Long- versus short-term androgen deprivation therapy with high-dose radiotherapy for biochemical failure after radical prostatectomy: a randomized controlled trial.
Charlien BerghenSteven JoniauAnnouschka LaenenGaetan DevosKato RansKarolien GoffinKarin HaustermansGert De MeerleerPublished in: Future oncology (London, England) (2020)
Radical prostatectomy is a well-established treatment option in the management of localized and locally advanced prostate cancer. An extended lymphadenectomy is performed in case of substantial risk for lymph node involvement. When biochemical recurrence (BCR) occurs, salvage radiotherapy (SRT) is performed. The benefit in terms of BCR-free survival (FS) and metastasis-FS by adding 6 months of androgen deprivation therapy (ADT) compared with SRT only has already been established. Retrospective evidence suggests that a longer schedule of ADT may be more beneficial compared with 6 months. This multicenter open-label randomized trial will include patients who need SRT after experiencing BCR post-radical prostatectomy with lymphadenectomy and pN0-status. Patients will be randomized for ADT duration (6 vs 24 months). Primary end point is distant metastasis-FS. Clinical Trial Registration: NCT04242017 (ClinicalTrials.gov).
Keyphrases
- radical prostatectomy
- prostate cancer
- lymph node
- locally advanced
- open label
- free survival
- early stage
- clinical trial
- acute lymphoblastic leukemia
- neoadjuvant chemotherapy
- double blind
- phase ii
- sentinel lymph node
- high dose
- tyrosine kinase
- chronic myeloid leukemia
- phase iii
- rectal cancer
- squamous cell carcinoma
- end stage renal disease
- phase ii study
- radiation therapy
- low dose
- newly diagnosed
- chronic kidney disease
- lymph node metastasis
- ejection fraction
- prognostic factors
- radiation induced
- cross sectional
- stem cells
- robot assisted
- minimally invasive
- combination therapy